Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
(MG-010 + sorafenib) by Metagone Biotech for Non-Small Cell Lung Carcinoma: Likelihood of Approval
(MG-010 + sorafenib) is under clinical development by Metagone Biotech and currently in Phase II for Non-Small Cell Lung Carcinoma....
(MG-010 + sorafenib) by Metagone Biotech for Renal Cell Carcinoma: Likelihood of Approval
(MG-010 + sorafenib) is under clinical development by Metagone Biotech and currently in Phase II for Renal Cell Carcinoma. According...
(MG-010 + sorafenib) by Metagone Biotech for Solid Tumor: Likelihood of Approval
(MG-010 + sorafenib) is under clinical development by Metagone Biotech and currently in Phase II for Solid Tumor. According to...
(MG-010 + sorafenib) by Metagone Biotech for Hepatocellular Carcinoma: Likelihood of Approval
(MG-010 + sorafenib) is under clinical development by Metagone Biotech and currently in Phase II for Hepatocellular Carcinoma. According to...
(MG-010 + sorafenib) by Metagone Biotech for Colorectal Cancer: Likelihood of Approval
(MG-010 + sorafenib) is under clinical development by Metagone Biotech and currently in Phase II for Colorectal Cancer. According to...